SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus Cadila gains on receiving tentative approval from USFDA for Amlodipine Besylate, Benazepril Hydrochloride

01 Apr 2013 Evaluate

Cadila Healthcare is currently trading at Rs 747.80, up by 6.45 points or 0.87% from its previous closing of Rs 741.35 on the BSE.

The scrip opened at Rs 749.00 and has touched a high and low of Rs 750.85 and Rs 746.05 respectively. So far 253 shares were traded on the counter.

The BSE group 'A' stock of face value Rs 5 has touched a 52 week high of Rs 964.00 on 12-Sep-2012 and a 52 week low of Rs 695.00 on 16-Apr-2012.

Last one week high and low of the scrip stood at Rs 750.85and Rs 714.20 respectively. The current market cap of the company is Rs 15179.03 crore.

The promoters holding in the company stood at 74.79% while Institutions and Non-Institutions held 16.32% and 8.89% respectively.

Zydus Cadila has received tentative approval from the USFDA for Amlodipine Besylate and Benazepril Hydrochloride capsules, which fall under the anti-hypertensive drug segment. The company received US Food and Drug Administration’s (USFDA) tentative nod for the formulation in the strengths of 2.5 mg/10 mg, 5 mg/10 mg, 5 mg/20 mg and 10 mg/20 mg.

As per IMS, the estimated sale for Amlodipine Besylate and Benazepril Hydrochloride capsules in 2012 was $384.8 million.

The group now has 78 approvals and has so far filed 173 abbreviated new drug applications (ANDAs) since the commencement of the filing process in 2003-04.

Zydus Lifesciences Share Price

939.20 3.20 (0.34%)
16-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1693.15
Dr. Reddys Lab 1221.25
Cipla 1230.75
Zydus Lifesciences 939.20
Lupin 2326.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×